Roth 'Encouraged' by Progress in Phase II GANNET53; Reaffirms Synta (SNTA) at 'Buy'
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $13 price target on Synta Pharmaceuticals Corp. (SNTA) after the company announced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
